Ash2l-a Super-Enhancer Binding for iPSC Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms and signaling networks orchestrating super-enhancer activity in cell reprogramming and pluripotency maintenance are poorly understood, particularly the role of Ash2l in regulating pluripotency and stemness.
Innovation Solution
Ash2l-a interacts with the Oct4-stemness circuitry to promote super-enhancer-driven pluripotency networks by binding to super-enhancers of Jarid2, Nanog, and Sox2, facilitating the formation of an Ash2l-a/OSN complex that drives enhancer activation and upregulation of stemness genes, thereby maintaining pluripotency and self-renewal in pluripotent stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming methods are used to convert somatic cells into iPSCs, then cell reprogramming can be achieved, but the efficiency is low and the mechanisms are poorly understood
Solution Approach 1:
The patent introduces Ash2l-a as an intermediary factor that mediates between the transcription factors (Oct4, Sox2, Nanog) and super-enhancers. Ash2l-a binds to super-enhancers and facilitates the formation of the OSN complex, thereby improving reprogramming efficiency while elucidating the mechanistic role of super-enhancers in pluripotency establishment
Solution Approach 2:
The patent identifies and characterizes the preliminary actions required for successful reprogramming by demonstrating that Ash2l-a must first bind to super-enhancers before the OSN complex can be formed. This preliminary binding event is crucial for subsequent pluripotency gene activation and efficient reprogramming
2Reliability
If super-enhancer activity is enhanced to drive pluripotency network, then pluripotency maintenance is improved, but the regulatory network complexity increases
Solution Approach 1:
The patent segments the complex regulatory network into distinct functional modules: Ash2l-a binding to super-enhancers, OSN complex formation, and downstream gene activation. This segmentation simplifies the understanding of how super-enhancers drive pluripotency by breaking down the regulatory cascade into manageable, experimentally tractable components
Solution Approach 2:
Ash2l-a serves as a key intermediary that connects super-enhancer regions to the OSN transcription factor complex. By identifying this intermediary role, the patent simplifies the complex regulatory network into a clearer sequence of events: Ash2l-a recruitment → OSN complex assembly → pluripotency gene expression
Data Source
AI summary
The preset invention relates to a novel super-enhancer-bound Ash2l/OSN complex that can drive enhance activation, govern pluripotency network and sternness circuitry, and a reprogramming system or method through the regulation of this super-enhancer, Ash2l, to modulate pluripotency and cell fates. Ash2l directly binds to super-enhancers of several stemness genes to regulate pluripotency and self-renewal in pluripotent stem cells. Ash2l recruits Oct4/Sox2/Nanog (OSN) to form Ash2l/OSN complex at the super-enhancers of Jarid2, Nanog, Sox2, and Oct4, and further drives enhancer activation, upregulation of stemness genes, and maintains the pluripotent circuitry. Ash2l knockdown abrogates the OSN recruitment to all super-enhancers and further hinders the enhancer activation. In addition, CRISPRi/dCas9-mediated blocking of Ash2l-binding motifs at these super-enhancers also prevents OSN recruitment and enhancer activation, validating that Ash2l directly binds to super-enhancers and initiates the pluripotency network. Transfection of Ash2l with W118A mutation to disrupt Ash2l-Oct4 interaction fails to rescue Ash2l-driven enhancer activation and pluripotent gene upregulation in Ash2l-depleted pluripotent stem cells.